Literature DB >> 9136992

Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades.

R Gum1, H Wang, E Lengyel, J Juarez, D Boyd.   

Abstract

The 92 kDa type IV collagenase (MMP-9), which degrades type IV collagen, has been implicated in tissue remodeling. The purpose of the current study was to determine the role of Jun amino-terminal kinase (JNK)- and extracellular signal-regulated kinase- (ERK)-dependent signaling cascades in the regulation of MMP-9 expression. Towards this end, we first determined the transcriptional requirements for MMP-9 promoter activity in a cell line (UM-SCC-1) which is an avid secretor of this collagenase. Transfection of these cells with a CAT reporter driven by progressive 5' deleted fragments of the MMP-9 promoter indicated the requirement of a region spanning -144 to -73 for optimal promoter activity. DNase I footprinting revealed a protected region of the promoter spanning nucleotides -91 to -68 and containing a consensus AP-1 motif at -79. Mutation of this AP-1 motif practically abolished the activity of the MMP-9 promoter-driven CAT reporter. Mobility shift assays indicated c-Fos and Jun-D bound to this motif and transfection of the cells with a mutated c-Jun, which quenches the function of endogenous Jun and Fos proteins, decreased MMP-9 promoter activity by 80%. UM-SCC-1 cells contained a constitutively activated JNK and the expression of a kinase-deficient JNK1 reduced the activity of a CAT reporter driven either by the MMP-9 promoter or by three tandem AP-1 repeats upstream of a thymidine kinase minimal promoter. Conditioned medium collected from UM-SCC-1 cells transfected with the dominant negative JNK1 expression vector diminished 92 kDa gelatinolysis. Similarly, interfering with MEKK, which lies upstream of JNK1, using a dominant negative expression vector reduced MMP-9 promoter activity over the same concentration range which repressed the AP-1-thymidine kinase CAT reporter construct. UM-SCC-1 cells also contained a constitutively activated ERK1. MMP-9 expression, as determined by CAT assays and by zymography, was reduced by the co-expression of a kinase-deficient ERK1. Interfering with MEK1, which is an upstream activator of ERK1, either with PD 098059, which prevents the activation of MEK1, or with a dominant negative expression construct, reduced 92 kDa gelatinolysis and MMP-9 promoter activity respectively. c-Raf-1 is an upstream activator of MEK1 and a kinase-deficient c-Raf-1 expression construct decreased the activity of a promoter driven by either the MMP-9 promoter or three tandem AP-1 repeats. Conversely, treatment of UM-SCC-1 cells with PMA, which activates c-Raf-1, increased 92 kDa gelatinolysis. These data suggest that MMP-9 expression in UM-SCC-1 cells, is regulated by JNK- and ERK-dependent signaling pathways.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9136992     DOI: 10.1038/sj.onc.1200973

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

1.  Transcriptional inhibition of matrix metalloproteinase 9 (MMP-9) activity by a c-fos/estrogen receptor fusion protein is mediated by the proximal AP-1 site of the MMP-9 promoter and correlates with reduced tumor cell invasion.

Authors:  D L Crowe; T N Brown
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression.

Authors:  D L Crowe; K J Tsang; B Shemirani
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

3.  Development of paramagnetic probes for molecular recognition studies in protein kinases.

Authors:  Jesus Vazquez; Surya K De; Li-Hsing Chen; Megan Riel-Mehan; Aras Emdadi; Jason Cellitti; John L Stebbins; Michele F Rega; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2008-06-26       Impact factor: 7.446

4.  Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-ERK1/2-mediated mechanism in primary human lung fibroblasts.

Authors:  Pedro A Ruiz; Gabor Jarai
Journal:  J Biol Chem       Date:  2011-02-18       Impact factor: 5.157

5.  Extract of Makgeolli suldeot downregulates NF-κB-mediated MMP-9 expression, thereby inhibiting invasive activity in a human breast cancer cell line, MDA-MB-231.

Authors:  Sang-Jin Lee; Sunyoung Park; Gyu-Un Bae; Hye Yoon Park; Changmu Kim; Cheon-Seok Park; Gye-Won Kim
Journal:  Food Sci Biotechnol       Date:  2016-06-30       Impact factor: 2.391

6.  Regulation of expression of matrix metalloproteinase-9 by JNK in Raw 264.7 cells: presence of inhibitory factor(s) suppressing MMP-9 induction in serum and conditioned media.

Authors:  Yun Song Lee; Huong Thi Lan Tran; Quang Van Ta
Journal:  Exp Mol Med       Date:  2009-04-30       Impact factor: 8.718

7.  Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract.

Authors:  Sang Eun Kim; Tran Thi Thanh Thuy; Ji Hyun Lee; Jai Youl Ro; Young An Bae; Yoon Kong; Jee Yin Ahn; Dong Soon Lee; Yeon Mock Oh; Sang Do Lee; Yun Song Lee
Journal:  Exp Mol Med       Date:  2009-04-30       Impact factor: 8.718

8.  Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.

Authors:  Ben Davidson; Vered Givant-Horwitz; Philip Lazarovici; Björn Risberg; Jahn M Nesland; Claes G Trope; Erik Schaefer; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

9.  Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion.

Authors:  X N Meng; Y Jin; Y Yu; J Bai; G Y Liu; J Zhu; Y Z Zhao; Z Wang; F Chen; K-Y Lee; S B Fu
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

10.  CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion.

Authors:  P A Havre; M Abe; Y Urasaki; K Ohnuma; C Morimoto; N H Dang
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.